Gilead and Merck to Collaborate on Long-Acting HIV Treatment
March 16, 2021
The companies will combine combining Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen aimed at treating HIV.